THE government is promoting the use of an injectable HIV drug — Cabotegravir long-acting (CAB-LA) pre-exposure prophylaxis (PrEP). According to the World Health Organisation, CAB-LA is a PrEP for HIV and has called for all countries to consider what it says is a safe and highly effective prevention option for people at substantial risk of…
To access this content, please purchase a subscription by clicking the button below and select a package of your choice!
Subscriptions